Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 30, 2014, Pages 11007-11012

  Oh, Misook ^a,b   Lee, Ji Hoon ^b,d   Wang, Wei ^a   Lee, Hui Sun ^c   Lee, Woo Sirl ^b   Burlak, Christopher ^a   Im, Wonpil ^c   Hoang, Quyen Q ^a   Lim, Hyun Suk ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c UNIVERSITY OF KANSAS   (United States)

^d Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

Author keywords

Chemical biology; Drug discovery; Helical mimetic

Indexed keywords

CHEMICAL BIOLOGY; DRUG DISCOVERY; HELICAL MIMETIC;

ALPHA-SYNUCLEIN; DRUG DISCOVERY; HUMANS; JURKAT CELLS; MOLECULAR CHAPERONES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PARKINSON DISEASE;

EID: 84904961684     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320556111     Document Type: Article

References (65)

1. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727-730. (Pubitemid 37361545)
2. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Drug Discov 3(4):301- 317.
3. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172):1001-1009. (Pubitemid 350273630)
4. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426(6968):905-909. (Pubitemid 38056884)
5. Winklhofer KF, Tatzelt J, Haass C (2008) The two faces of protein misfolding: Gain- and loss-of-function in neurodegenerative diseases. EMBO J 27(2):336-349. (Pubitemid 351161650)
6. Arakawa T, Ejima D, Kita Y, Tsumoto K (2006) Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764(11):1677-1687. (Pubitemid 46053854)
7. Leandro P, Gomes CM (2008) Protein misfolding in conformational disorders: Rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 8(9):901-911.
8. Ringe D, Petsko GA (2009) What are pharmacological chaperones and why are they interesting? J Biol 8(9):80.
9. Thanos CD, DeLano WL, Wells JA (2006) Hot-spot mimicry of a cytokine receptor by a small molecule. Proc Natl Acad Sci USA 103(42):15422-15427. (Pubitemid 44625607)
10. Brenke R, et al. (2009) Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25(5):621-627.
11. Landon MR, et al. (2009) Detection of ligand binding hot spots on protein surfaces via fragment-based methods: Application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 23(8):491-500.
12. Pey AL, et al. (2004) Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat 24(5):388- 399.
13. Lieberman RL, et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3(2):101-107. (Pubitemid 46134996)
14. Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 20(1):54-62.
15. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL (2007) Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc 129(9):2456-2457. (Pubitemid 46364050)
16. Henchey LK, et al. (2010) Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix. J Am Chem Soc 132(3):941-943.
17. Mills NL, Daugherty MD, Frankel AD, Guy RK (2006) An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction. J Am Chem Soc 128(11):3496-3497.
18. Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem 5(3):161-173.
19. Cummings CG, Hamilton AD (2010) Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol 14(3):341-346.
20. Heeres JT, Hergenrother PJ (2011) High-throughput screening for modulators of protein-protein interactions: Use of photonic crystal biosensors and complementary technologies. Chem Soc Rev 40(8):4398-4410.
21. Horswill AR, Savinov SN, Benkovic SJ (2004) A systematic method for identifying small-molecule modulators of protein-protein interactions. Proc Natl Acad Sci USA 101(44):15591-15596. (Pubitemid 39473532)
22. Henchey LK, Jochim AL, Arora PS (2008) Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. Curr Opin Chem Biol 12(6):692-697.
23. Phillips C, et al. (2011) Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc 133(25):9696-9699.
24. Goodman CM, Choi S, Shandler S, DeGrado WF (2007) Foldamers as versatile frameworks for the design and evolution of function. Nat Chem Biol 3(5):252-262. (Pubitemid 46628637)
25. Horne WS, Gellman SH (2008) Foldamers with heterogeneous backbones. Acc Chem Res 41(10):1399-1408.
26. Seebach D, Gardiner J (2008) Beta-peptidic peptidomimetics. Acc Chem Res 41(10):1366-1375.
27. Hara T, Durell SR, Myers MC, Appella DH (2006) Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J Am Chem Soc 128(6):1995-2004. (Pubitemid 43277340)
28. Chongsiriwatana NP, et al. (2008) Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci USA 105(8):2794-2799. (Pubitemid 351723623)
29. Kritzer JA, Luedtke NW, Harker EA, Schepartz A (2005) A rapid library screen for tailoring beta-peptide structure and function. J Am Chem Soc 127(42):14584-14585. (Pubitemid 41510993)
30. Tosovská P, Arora PS (2010) Oligooxopiperazines as nonpeptidic alpha-helix mimetics. Org Lett 12(7):1588-1591.
31. Volonterio A, Moisan L, Rebek J, Jr (2007) Synthesis of pyridazine-based scaffolds as alpha-helix mimetics. Org Lett 9(19):3733-3736.
32. Maity P, König B (2008) Synthesis and structure of 1,4-dipiperazino benzenes: Chiral terphenyl-type peptide helix mimetics. Org Lett 10(7):1473-1476.
33. Min J, et al. (2007) Forward chemical genetic approach identifies new role for GAPDH in insulin signaling. Nat Chem Biol 3(1):55-59. (Pubitemid 46005699)
34. Angell Y, Chen D, Brahimi F, Saragovi HU, Burgess K (2008) A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics. J Am Chem Soc 130(2):556-565. (Pubitemid 351455569)
35. Popowicz GM, Dömling A, Holak TA (2011) The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl 50(12):2680-2688.
36. Marimganti S, Cheemala MN, Ahn JM (2009) Novel amphiphilic alpha-helix mimetics based on a bis-benzamide scaffold. Org Lett 11(19):4418-4421.
37. Thompson S, Hamilton AD (2012) Amphiphilic α-helix mimetics based on a benzoylurea scaffold. Org Biomol Chem 10(30):5780-5782.
38. Jung KY, et al. (2013) Amphipathic α-helix mimetics based on a 1,2-diphenylacetylene scaffold. Org Lett 15(13):3234-3237.
39. Shahian T, et al. (2009) Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat Chem Biol 5(9):640-646.
40. Shaginian A, et al. (2009) Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc 131(15):5564-5572.
41. Lee JH, et al. (2011) Novel pyrrolopyrimidine-based α-helix mimetics: Cell-permeable inhibitors of protein-protein interactions. J Am Chem Soc 133(4):676-679.
42. Lam KS, et al. (1991) A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354(6348):82-84. (Pubitemid 21896787)
43. Joo SH, Xiao Q, Ling Y, Gopishetty B, Pei D (2006) High-throughput sequence determination of cyclic peptide library members by partial Edman degradation/mass spectrometry. J Am Chem Soc 128(39):13000-13009. (Pubitemid 44527779)
44. Lee JH, Meyer AM, Lim HS (2010) A simple strategy for the construction of combinatorial cyclic peptoid libraries. Chem Commun (Camb) 46(45):8615-8617.
45. Lee JH, Kim HS, Lim HS (2011) Design and facile solid-phase synthesis of conformationally constrained bicyclic peptoids. Org Lett 13(19):5012- 5015.
46. Aquino C, et al. (2012) A biomimetic polyketide-inspired approach to small-molecule ligand discovery. Nat Chem 4(2):99-104.
47. Astle JM, et al. (2010) Seamless bead to microarray screening: Rapid identification of the highest affinity protein ligands from large combinatorial libraries. Chem Biol 17(1):38-45.
48. Kodadek T (2010) Rethinking screening. Nat Chem Biol 6(3):162-165.
49. Arkin MR, et al. (2003) Binding of small molecules to an adaptive protein-protein interface. Proc Natl Acad Sci USA 100(4):1603-1608. (Pubitemid 36254494)
50. Liu R, Marik J, Lam KS (2002) A novel peptide-based encoding system for "one-bead one-compound" peptidomimetic and small molecule combinatorial libraries. J Am Chem Soc 124(26):7678-7680. (Pubitemid 34733779)
51. Kwon YU, Kodadek T (2008) Encoded combinatorial libraries for the construction of cyclic peptoid microarrays. Chem Commun (Camb) (44):5704-5706.
52. Simon RJ, et al. (1992) Peptoids: A modular approach to drug discovery. Proc Natl Acad Sci USA 89(20):9367-9371.
53. Gorske BC, Jewell SA, Guerard EJ, Blackwell HE (2005) Expedient synthesis and design strategies for new peptoid construction. Org Lett 7(8):1521-1524. (Pubitemid 40585921)
54. Olivos HJ, Alluri PG, Reddy MM, Salony D, Kodadek T (2002) Microwave-assisted solid-phase synthesis of peptoids. Org Lett 4(23):4057-4059.
55. Lessene G, Czabotar PE, Colman PM (2008) BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7(12):989-1000.
56. Oltersdorf T, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677-681. (Pubitemid 40825512)
57. van Delft MF, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389-399. (Pubitemid 44711953)
58. Stewart ML, Fire E, Keating AE, Walensky LD (2010) The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6(8):595-601.
59. Müller CE (2009) Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem Biodivers 6(11):2071-2083.
60. Mezey E, et al. (1998) Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? Nat Med 4(7):755-757. (Pubitemid 28331004)
61. Fink AL (2006) The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 39(9):628-634.
62. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35(43):13709-13715. (Pubitemid 26363912)
63. Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362):107-110.
64. Wang W, et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108(43):17797-17802.
65. Chandra S, Chen X, Rizo J, Jahn R, Südhof TC (2003) A broken alpha -helix in folded alpha -Synuclein. J Biol Chem 278(17):15313-15318. (Pubitemid 36799869)